Drug intelligence / Profile preview

MAN-01

Development stage: Preclinical
Lead developer: Q BioMed
Modality: Small Molecules
Administration: Ophthalmic

Overview

MAN-01 is an investigational small molecule drug candidate developed for the treatment of intraocular eye pressure, specifically targeting Schlemm's Canal in the eye. It is positioned as a first-in-class therapy for conditions such as glaucoma by modulating outflow through this critical anatomical structure[1]. Additionally, under the name "Cannabinoid-MAN01," it has been described as a chemical drug with potential applications in central nervous system diseases. The compound was initially developed by TRx Biosciences Limited and further advanced by Mandara Sciences LLC (Mandara Pharma)[2]. Its mechanism of action and specific molecular targets have not been publicly disclosed.

Other names: Cannabinoid-MAN01Cannabinoid-MAN-01Cannabinoid-MAN 01

Targets

TEK (Tie2)

Beyond the preview

Go deeper on MAN-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MAN-01.

Explore the full profile